ViiV has announced a public tender agreement with the Ministry of Health in Botswana for its HIV drug dolutegravir.
Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.
Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.
ViiV has announced a public tender agreement with the Ministry of Health in Botswana for its HIV drug dolutegravir.
Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric… Powered by WPeMatico
The widely accepted principle that mums-to-be are a ‘vulnerable’ group unfairly excludes them from taking part in clinical studies, and perpetuates the knowledge void around the impact of drugs taken… Powered by WPeMatico
Mapi, a developer of Linguistic Validation and most trusted provider of Clinical Outcome Assessments, is collaborating with YPrime, a clinical research technology provider, to streamline the deployment of validated Assessments migrated onto YPrime’s eCOA platform. Mapi Language services and YPrime are leveraging cloud level integrations between technology platforms to establish a seamless operational interface between Mapi’s ISO 17100 certified process and YPrime’s eCOA platform […]
Battelle’s Board of Directors announced that Lewis “Lou” Von Thaer has been selected as president and CEO of Battelle, the 9th CEO in the company’s 87-year history. Von Thaer, who has extensive leadership experience in diverse markets, including engineering, intelligence and other federal contracting sectors, will officially begin his new role on October 1, 2017. He […]
Helius Medical Technologies, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, and the United States Army Medical Research and Materiel Command (USAMRMC) announce that the last subject has been enrolled in the registrational clinical trial to investigate the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS) […]
Sangamo Therapeutics announced that the FDA has granted Fast Track designation to SB-318 and SB-913, the company’s clinical stage in vivo genome editing product candidates for the treatment of Mucopolysaccharidosis Type I (MPS I) and MPS II, respectively. The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs and biologics […]
